Kawa K. Ajgeiy

Odense, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis.

Journal: JAMA dermatology

Published: January 07, 2026

Changes in Drug Survival of Adalimumab Over Time in Patients with Psoriasis - A Nationwide Cohort Study.

Changes in Drug Survival of Adalimumab Over Time in Patients with Psoriasis - A Nationwide Cohort Study.

Journal: Clinical and experimental dermatology

Published: September 15, 2025

Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study.

Changes in drug survival of adalimumab over time in patients with psoriasis: a nationwide cohort study.

Journal: Clinical and experimental dermatology

Published: September 15, 2025

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.

Journal: Acta dermato-venereologica

Published: November 25, 2024

Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.

Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study.

Journal: Acta dermato-venereologica

Published: May 09, 2023

Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.

Drug survival of biologic therapies for palmoplantar pustulosis: A nationwide study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 29, 2023

Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort Study.

Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment - a Nationwide Cohort Study.

Journal: The Journal of investigative dermatology

Published: October 05, 2022

Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level.

Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level.

Journal: JAMA dermatology

Published: August 17, 2022

Incidence, Risk Factors, and Consequences of Human Alphaherpesvirus Infections in Patients With Psoriasis Who Initiate Methotrexate or Biologic Agents.

Incidence, Risk Factors, and Consequences of Human Alphaherpesvirus Infections in Patients With Psoriasis Who Initiate Methotrexate or Biologic Agents.

Journal: The Journal of infectious diseases

Published: June 15, 2022

Machine learning model for predicting outcomes of biologic therapy in psoriasis.

Machine learning model for predicting outcomes of biologic therapy in psoriasis.

Journal: Journal of the American Academy of Dermatology

Published: April 30, 2022

Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.

Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 22, 2021

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study.

Journal: Acta dermato-venereologica

Published: October 13, 2021

Showing 1-12 of 16

Last Updated: 09/26/2026